Teva QVAR Inhaler Antitrust Settlement

Paid for a QVAR Inhaler? You May Be Owed Money.

Teva Pharmaceuticals has agreed to pay $35 million to settle claims that it illegally blocked cheaper generic alternatives to its QVAR asthma inhaler. If you purchased or paid for QVAR or QVAR RediHaler between 2015 and 2025 in an eligible state, you may qualify for a cash payment.

Join Now
Teva QVAR Inhaler Antitrust Settlement

About the Case

Teva Pharmaceuticals has agreed to pay $35 million to resolve a class action lawsuit alleging it engaged in anticompetitive conduct to block generic competition for its QVAR and QVAR RediHaler asthma inhalers, keeping prices artificially high for consumers.

The lawsuit claims Teva illegally sought to prevent cheaper generic alternatives from entering the market, forcing consumers and their insurers to pay inflated prices for QVAR products.

Who Qualifies?

You may be eligible if you purchased, paid for, or provided reimbursement for QVAR® or QVAR RediHaler® inhalers between January 1, 2015 and July 31, 2025 in one of the 42 eligible states plus Washington, D.C.

How Much Can You Receive?

The exact payment amount is not yet determined and will depend on the number of products purchased and total number of valid claims filed. Payments will be distributed pro rata from the $35 million net settlement fund.

Claim deadline: July 31, 2026

Eligibility

You may be eligible if all of the following apply:

  • You purchased, paid for, or provided reimbursement for QVAR® or QVAR RediHaler® inhalers
  • Between January 1, 2015 and July 31, 2025
  • In one of the 42 eligible states plus Washington, D.C.

Case Details

Settlement Amount

$35M

Submission Deadline

July 31, 2026

Proof of Purchase

Helpful, not required

Join the Case